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SUMMARY In women with psoriasis, the course of the disease 
during conception, pregnancy and delivery generally does not differ 
from other individuals involved. In psoriasis patients, pre-pregnancy 
period offers time to learn about the hereditary nature of the disease, 
the effect of hormonal changes and acceptable treatments during 
pregnancy. In the majority of patients, psoriasis improved during 
pregnancy and worsened six weeks after delivery. Women should 
tell their dermatologist early if they plan to become pregnant and 
the treatment during pregnancy should be considered carefully. This 
article provides a short review of the most important literature data 
on therapeutic options for psoriasis in pregnancy. 
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INTRODUCTION
 Psoriasis is a common inflammatory skin dis-
ease characterized by infiltration of inflammatory 
cells into the epidermis and altered keratinocyte 
differentiation (1). Psoriasis affects about 25 mil-
lion people in North America and Europe, and is 
probably the most prevalent immune-mediated 
skin disease in adults (2). The incidence is simi-
lar for the two sexes, although women generally 
develop the disease earlier than men. Because 
the majority of psoriasis patients present before 
the age of 40, many female patients may become 
pregnant. Information regarding the heritability of 
psoriasis can be used on providing advice to pa-
tients that inquire about the potential risk to their 
children (3). If one parent is affected by psoriasis, 
the risk to offspring is 14%-15%. If both parents 
have psoriasis, the risk to offspring is 41%-75%. If 
neither parent has psoriasis but a child is affected, 
the risk to subsequent offspring is 6%-20% (4,5).
THE EFFECTS OF PREGNANCY ON 
PSORIASIS
 It is generally accepted that pregnancy has fa-
vorable effects on psoriasis (6). In a retrospective 
study by Raychaudhuri et al., data on the clinical 
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course of psoriasis during pregnancy were collect-
ed from Psoriasis Life History Questionnaires. In-
formation relevant for the clinical course of psoria-
sis during pregnancy was evaluated in respect to 
improvement/worsening, number of pregnancies, 
severity of disease, and some other clinical pa-
rameters. Results showed that psoriasis improved 
during pregnancy in the majority of patients. Data 
available from 91 pregnancies revealed that 
psoriasis improved in 51 (56%), worsened in 24 
(26.4%), and remained unchanged in 16 (17.6%) 
patients. Also, the appearance of new psoriasis le-
sions was quite frequent in the early postpartum 
period (7). In a study by Murase et al., the psoriatic 
body surface area was assessed 5 times over a 
year in pregnant patients with psoriasis and non-
pregnant, menstruating patients with psoriasis as 
a control group. During pregnancy, 55% of patients 
reported improvement, 21% reported no change, 
and 23% reported worsening. Postpartum, 9% of 
patients reported improvement, 26% reported no 
change, and 65% reported worsening (8). Boyd 
et al. suggest the improvement of psoriasis in 
pregnancy to be associated with high concentra-
tions of progesterone, which down-regulates T 
cell proliferative response (9). In contrast, Murase 
et al. found high levels of estrogen to correlate 
with improvement in psoriasis, whereas pro-
gesterone levels did not correlate with psoriatic 
change (8).
Pre-pregnancy period
 Most doctors recommend that women suffer-
ing from psoriasis and considering pregnancy 
visit dermatologist to talk about everything that 
is connected with psoriasis and pregnancy. Pre-
pregnancy is a perfect time to talk about genetic 
risk factors and treatments that will be safe during 
pregnancy and breastfeeding. 
 Psoriasis does not affect fertility or rates of mis-
carriage, birth defects, or premature delivery (10). 
Most of the information available on the use of 
medication during pregnancy is derived from case 
reports or retrospective collections of pregnancy 
outcomes in clinical series (11).
 One reason why there is so little information re-
garding the use of medications during pregnancy 
is because there is selective bias against studies 
in pregnant women for ethical reasons (11). Most 
information on the effects of fetal exposure comes 
from inadvertent exposures by women who did not 
know they were pregnant at the time they were 
taking the medication (11). 
TOPICAL TREATMENTS
 Topical treatments are first line treatments 
for psoriasis. The potential absorption of topical 
medications through the skin must be considered. 
Emollients, anthralin (dithranol) and topical ste-
roids are considered safe in pregnancy (10).
Anthralin 
 Anthralin is among the oldest topical treat-
ments for psoriasis and it has been used safely for 
decades in pregnant women. No animal or human 
studies have examined the potential birth defects 
associated with the use of anthralin (10,11). Par-
ticular attention has been paid to the anthralin po-
tential renal toxicity, but no evidence of systemic 
absorption or toxicity has been associated with 
topical anthralin treatment (12,13).
Corticosteroids
 Topical corticosteroids are the most commonly 
used therapy for localized psoriatic plaques gen-
erally and also in pregnancy. It is believed that the 
usual treatment of pregnant women with topical 
corticosteroids is associated with little, if any, tera-
togenic risk (11). This belief is supported by sever-
al studies of corticosteroid use during pregnancy 
(14-16). If topical steroids are required, the amount 
should be limited. The degree of systemic absorp-
tion depends on many factors such as dose, use 
of occlusion, amount of surface area treated, num-
ber of applications, and duration of treatment (11). 
The more potent corticosteroids have been found 
to be absorbed in sufficient amounts to cause sys-
temic effects such as adrenal suppression (6,11).
 Lam et al. suggest a conservative approach to 
warn pregnant women not to use large amounts of 
topical corticosteroids over extensive parts of the 
body because of the possibility of having a new-
born with low birth weight (11).
Salicylic acid 
 After topical application of salicylic acid or its 
derivatives, between 9% and 25% of salicylic acid 
has been reported to be systemically absorbed 
(17,18). This small systemic absorption and the 
lack of adverse reports suggest a low teratogenic 
potential of topical salicylic acid. Pregnant women 
should be warned against applying preparations 
containing topical salicylic acid over large areas 
of their bodies for prolonged periods of time (11). 
They should also be advised that combining topi-
cal salicylic acid with other medications and the 
use of occlusive dressing can potentially increase 
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the systemic toxicity and teratogenic risk of topical 
salicylic acid (11).
Calcipotriene
 Approximately 6% of calcipotriene, a synthet-
ic vitamin D3 derivative, is absorbed systemi-
cally when the ointment is applied onto psoriatic 
plaques (3). There are no publications regarding 
topical use of calcipotriene in pregnant women (3). 
The use of topical calcipotriene during pregnancy 
at recommended doses is unlikely to be associ-
ated with a high risk of teratogenicity (11).
Tacrolimus
 Tacrolimus, a macrolide immunosuppressant, 
has not yet been approved for the treatment of 
psoriasis, although some studies have shown 
favorable results in facial and intertriginous pso-
riasis (19,20). Systemic absorption of tacrolimus 
after topical application is very low and is not as-
sociated with systemic effects (21). There are no 
literature reports on women using tacrolimus topi-
cally during pregnancy (11). 
Topical retinoids (tazarotene)
 Topical tazarotene is approved for the treatment 
of psoriasis but it is recommended that tazarotene 
should be stopped immediately if the woman be-
comes pregnant while using it (22). Large doses 
of tazarotene caused fetal abnormalities in some 
animal studies, but no teratogenic effects occurred 
in human clinical studies (11,23).
 It is generally advised not to use tazarotene in 
pre-pregnancy period and during pregnancy (3).
 UVB phototherapy
 UVB phototherapy UVB is considered to be a 
safe and effective form of treatment for psoriasis 
in pregnancy and there are no contraindications 
for its use (3,11,25). Treatment with UVB can be 
initiated in pregnant patients whose psoriasis has 
become more widespread and cannot be man-
aged by topical treatments alone (3). During UVB 
phototherapy sunscreens should be applied on 




 PUVA (photochemotherapy) is contraindicated 
in pregnancy because both components in PUVA 
treatment, the oral medication psoralen and the 
UVA light, are potentially mutagenic (24). Photo-
activation of psoralens has been found to be mu-
tagenic and induce sister chromatid exchanges 
in vitro (11,25). This also applies to bath PUVA, 
where the entire body is immersed in a tub of wa-
ter that contains psoralen. It should be noted that 
no adverse fetal outcomes have been reported for 
women that became pregnant while being treated 
with PUVA (10,26,27).
 Topical PUVA for patients with localized pso-
riasis of the palm and sole showed no adverse 
systemic effects and undetectable blood levels of 
8-methoxypsoralen; however, it cannot be recom-
mended because of the mutagenic potential of 
PUVA (10,24,26).
Systemic retinoids
 Retinoids are vitamin A derivatives and the 
retinoids etretinate and isotretinoin are on the list 
of known human teratogens; so, they should be 
avoided in pregnancy (3). The relative risk of fetal 
malformation in pregnancies exposed to an oral 
retinoid in early pregnancy is 25.6 times that in the 
general population (11,28). With fetal exposure to 
oral retinoids, there is a characteristic pattern of 
malformation involving craniofacial, cardiac, thy-
mic and central nervous system structures (11).
 It has been suggested that women of child-
bearing potential that require oral retinoid thera-
py for the treatment of psoriasis should consider 
isotretinoin rather than acitretin (3). Although 
both are potent teratogens, pregnancy can be 
safely initiated one month after discontinuation of 
isotretinoin therapy versus three years in case of 
acitretin (3,29). Isotretinoin is typically used in the 
treatment of severe acne, but it has been shown to 
flatten plaques and reduce desquamation in cases 
of psoriasis, particularly in combination with PUVA 
(30,31).
 Teratogenic effect of all retinoids should be 
carefully considered before being prescribed to 
any woman of childbearing potential (10).
Cyclosporine 
 Most of the reports of prenatal effects of cyclo-
sporine come from its use in patients undergoing 
transplantation (11,32). No recurrent pattern of con-
genital anomalies has been described among chil-
dren born to women that were treated with cyclo-
sporine during pregnancy, although low birth weight 
and premature birth were traced to cyclosporine 
use (11,33,34). There are no specific contraception 
guidelines when taking cyclosporine (24).
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 In general, cyclosporine should only be used 
during pregnancy under careful clinical judgment 
if the potential benefit outweighs the potential risk 
(35). Cyclosporine is not known to affect male fer-
tility (36).
Methotrexate
 Methotrexate (MTX) is contraindicated in preg-
nancy because it is associated with spontaneous 
miscarriage, cleft palate and skeletal abnormali-
ties (10). An effective method of contraception 
should be used in women receiving methotrexate 
(22). Both men and women should discontinue 
methotrexate for at least 12 weeks before trying to 
conceive (22,37). Methotrexate may lower sperm 
count temporarily but it then returns to normal (37). 
Methotrexate poses little or no risk to pregnancies 
that occur after it has been discontinued (38). It 
does not harm male or female long-term potential 
of conceiving a healthy child (38).
Biologics
 Limited data are available on the use of biolog-
ics in pregnancy. Manufacturers of etanrecept and 
infliximab, which are licensed for use in severe 
psoriasis, advise avoidance in pregnancy (10).
CONCLUSION
 An appropriate general approach to women 
of childbearing age who have psoriasis involves 
open communication between the clinician and the 
patient (3). Treatment of a pregnant woman with 
psoriasis should take into consideration therapeu-
tic benefit to her and her fetus, and the availabil-
ity of safe and effective alternatives (11). Hardly 
any controlled trials on the treatment of psoriasis 
in pregnancy, evaluating the effect and safety of 
different drugs, can be found in the literature. The 
most important therapeutic approach is to keep 
psoriasis under control during pregnancy. 
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